諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） InnoCare Pharma Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 承董事會命 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及及管坤良教授。 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2025年8月19日（星期二）舉行董事會會議，藉以（其中包括）考慮並批准本公司 及其附屬公司截至2025年6月30日止六個月中期業績及其發佈。 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，2025年8月5日 董事會召開日期 ...

Core Viewpoint - The Hong Kong stock market continued its rebound, with significant net inflows from mainland investors exceeding HKD 22 billion, leading to gains in major indices [1] Group 1: Market Performance - The Hang Seng Index rose by 0.68%, the Hang Seng China Enterprises Index increased by 0.65%, and the Hang Seng Tech Index gained 0.73% [1] - Large technology stocks showed mixed performance, with Kuaishou up nearly 3%, Tencent rising by 1.64%, and Netease increasing by 1.55%, while Xiaomi, Alibaba, Baidu, and Meituan remained in the red [1] Group 2: Sector Highlights - Biopharmaceutical stocks experienced a significant surge, with Junshi Biosciences soaring nearly 34% at the close, and other companies like CanSino Biologics, Innovent Biologics, and WuXi AppTec also showing strong performance [1] - Leading paper companies initiated a new round of price increases, resulting in a notable rise in paper stocks, with Chenming Paper up nearly 15% reaching a new high [1] - The brain-computer interface concept stocks generally rose, with Nanjing Panda Electronics hitting an intraday high of 8% [1] Group 3: Other Sector Movements - The automotive sector showed mixed results following the release of July's new energy vehicle sales data, with NIO, Leapmotor, and BYD underperforming [1] - Semiconductor stocks declined in the afternoon, with SMIC falling nearly 1%, while lithium battery stocks, education stocks, and oil stocks saw slight declines [1]

Core Viewpoint - The company, Innovent Biologics (09969.HK), has announced that it will hold a board meeting on August 19, 2025, to consider and approve its interim results for the six months ending June 30, 2025 [1] Summary by Relevant Categories - **Company Announcement** - Innovent Biologics will hold a board meeting on August 19, 2025 [1] - The meeting will focus on considering and approving the interim results for the six months ending June 30, 2025 [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,494,598,235 | | 1,686,000 | | 1,496,284,235 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,494,598,235 | | 1,686,000 | | 1,496,28 ...

（股份代號：9969） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，2025年8月5日 董事會召開日期 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及及管坤良教授。 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2025年8月19日（星期二）舉行董事會會議，藉以（其中包括）考慮並批准本公司 及其附屬公司截至2025年6月30日止六個月中期業績及其發佈。 承董事會命 ...

港股三大指数延续昨日反弹行情，南下资金净买入港股超220亿港元！截止收盘，恒生指数涨0.68%， 国企指数涨0.65%，恒生科技指数涨0.73%。盘面上，大型科技股走势分化，其中，快手涨近3%，腾讯 涨1.64%，网易涨1.55%，小米、阿里巴巴、百度、美团仍旧飘绿；生物医药股再度迎来大涨行情，君 实生物尾盘快速拉升大幅上涨近34%表现十分抢眼，康诺亚、复宏汉霖、诺诚健华、药明康德皆走强； 纸企龙头发起新一轮涨价潮，纸业股拉升明显，晨鸣纸业大涨近15%刷新阶段新高；近期行业利好袭 来，脑机接口概念股普遍上涨，南京熊猫电子盘中涨至8%，钢铁股、苹果概念股、濠赌股、核电股、 重型机械股、航空股、保险股、内银股、煤炭股多数表现活跃。另一方面，7月新能源车销量成绩单发 布，汽车股涨跌不一，蔚来汽车、零跑汽车、比亚迪股份全天表现低迷，半导体股午后走低，中芯国际 转跌近1%，锂电池股、教育股、石油股少部分走低。(格隆汇) ...

Group 1 - The core viewpoint of the articles highlights the significant growth and activity in the Hong Kong innovative drug sector, with the Hong Kong Innovative Drug 50 ETF (513780) experiencing a year-to-date increase of approximately 100% [1] - Notable individual stocks in the innovative drug sector include Ascentage Pharma-B, which rose over 10%, and others like CanSino Biologics and Lepu Biopharma-B, which increased by more than 7% [1] - The net inflow of funds into the Hong Kong Innovative Drug 50 ETF has been substantial, with a total net inflow of 526 million yuan over the last nine trading days and over 800 million yuan in the past three months, indicating accelerated capital deployment [1] Group 2 - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for a cumulative weight of 70.19%, including high-quality A-share companies like Innovent Biologics and CSPC Pharmaceutical Group [2] - The innovative drug sector in China is at a new historical starting point, with domestic companies enhancing their competitiveness and expanding overseas, while industry revenue is rapidly growing and moving towards a profit-driven new cycle [2] - Strong policy support is crucial for the development of the innovative drug industry, providing a favorable environment for growth and investment opportunities [2]

（文章来源：每日经济新闻） 每经AI快讯，港股创新药板块继续走强，亚盛医药-B涨逾10%，康诺亚-B、乐普生物-B涨逾7%，诺诚 健华、信达生物涨超5%。 ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

Group 1 - The Hong Kong biotechnology stocks experienced a collective increase, with Beihai Kangcheng-B rising nearly 19% [1] - Gilead Sciences-B surged over 15%, while Ascentage Pharma-B increased by more than 9% [1] - Other notable gainers include Jiahe Biopharma-B up over 8%, and Beikang Medical-B, Fuhong Hanlin, and Kangnuo Ya-B each rising over 7% [1] Group 2 - Huakang Biomedical, Basilea Pharmaceutica-B, Lepu Biopharma-B, and Hualing Pharmaceutical-B all saw increases of over 6% [1] - Yiming Anke-B, Nocera Health, Zai Lab, and CanSino Biologics rose by more than 5% [1]